Capitalizing leadership acumen
for life science innovations

PITTSBURGH, Nov. 03, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will present in person a corporate overview at the Jefferies London Healthcare Conference being held November 16 - 18.

Jefferies London Healthcare Conference
Date:      Wednesday, November 17
Time:   8:40 a.m. – 9:15 a.m. GMT
Location:   Webcast Link
     

About NeuBase Therapeutics
NeuBase is accelerating the genetic revolution by developing a new class of precision genetic medicines which can be designed to increase, decrease, or change gene function, as appropriate, to resolve genetic defects that drive disease. NeuBase’s targeted PATrOL™ therapies are centered around its proprietary drug scaffold to address genetic diseases at the DNA or RNA level by combining the highly targeted approach of traditional genetic therapies with the broad organ distribution capabilities of small molecules. With an initial focus on silencing disease-causing mutations in debilitating neuromuscular, neurological and oncologic disorders, NeuBase is committed to redefining medicine for the millions of patients with both common and rare conditions. To learn more, visit www.neubasetherapeutics.com.

Investor Contact: 
Daniel Ferry 
LifeSci Advisors 
+1 (617) 430-7576 
This email address is being protected from spambots. You need JavaScript enabled to view it.

NeuBase Media Information:
Jessica Yingling, Ph.D.
Little Dog Communications Inc.
+1 (858) 344-8091
This email address is being protected from spambots. You need JavaScript enabled to view it.


Primary Logo

Source: NeuBase Therapeutics, Inc.